Physician

Stephen B Beck, M.D.

According to 2025 Medicare claims, Stephen Beck, M.D. (NPI: 1881612612) practices medical oncology in the Birmingham, AL market, with the plurality of this provider's patient population coming from Jefferson, AL. This provider's primary affiliated billing organization is BIRMINGHAM HEMATOLOGY ONCOLOGY ASSOC LLC (NPI: 1841216389; TIN: 522170293) and primary practice location at 35205-1202.

Beck's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 350 traditional Medicare patients, billed 93,258 HCPCS/CPT codes, and received $2,239,484 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,308 prescription claims across 348 beneficiaries totaling $4,805,534 in drug costs, led by Imbruvica (Ibrutinib). 2021 DME data shows 12 claims. Open Payments data shows 161 records totaling $3,269. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $2,156,929 and ending at $2,239,484. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,250,645 to $4,805,534. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	505	263,393	$2,156,929
2016	505	256,285	$2,722,137
2017	349	149,997	$1,593,289
2018	364	184,207	$2,398,251
2019	400	187,935	$2,342,606
2020	357	141,372	$1,966,682
2021	374	128,752	$1,682,945
2022	373	126,594	$1,716,082
2023	342	129,995	$1,945,487
2024	350	93,258	$2,239,484

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	324	2,138	$1,250,645
2016	298	1,933	$1,507,501
2017	265	1,708	$1,464,602
2018	246	2,057	$1,924,431
2019	263	2,084	$1,680,334
2020	265	1,952	$2,055,666
2021	297	2,149	$2,829,406
2022	343	2,256	$4,234,911
2023	328	2,341	$4,847,391
2024	348	2,308	$4,805,534

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	104	$7,268
2016	12	19	$1,519
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	12	$1,067
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	183	447	$86
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	151	208	$56
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	189	298	$12
96372	Injection of drug or substance under skin or into muscle	65	183	$9
36415	Insertion of needle into vein for collection of blood sample	297	669	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	55	1,540	$875,742
Brukinsa	Zanubrutinib	49	1,470	$723,852
Revlimid	Lenalidomide	42	1,043	$706,161
Xtandi	Enzalutamide	48	1,440	$689,484
Jakafi	Ruxolitinib Phosphate	23	690	$398,986

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	161	$3,269	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Stephen B. Beck, M.D.?

Tedicare shows public-source Medicare data for Stephen B. Beck, M.D. (NPI 1881612612), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Stephen B. Beck, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Stephen B. Beck, M.D.?

Stephen B. Beck, M.D. is linked to BIRMINGHAM HEMATOLOGY ONCOLOGY ASSOC LLC (billing NPI 1841216389) in the available physician profile data.

Does Stephen B. Beck, M.D. have Open Payments data?

Stephen B. Beck, M.D. has 161 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.